Mutant Tubulins and Tau: A Path toward Treatments for Alzheimer’s-Related Dementia
Official title: Mutant Tubulins Confer Resistance to Pathological Tau
Funded at Seattle Inst for Biomedical/clinical Res · NIH-11371185 · Data updated 2026-11-12
A scientist is studying how specific mutant tubulins may reduce harmful tau effects in brain cells, with the goal of finding ways to slow or alter Alzheimer’s-related dementia.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Inst for Biomedical/clinical Res NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $249,000 |
| NIH project number | 5R00AG073455-06 |
| Project ID | NIH-11371185 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with Alzheimer’s disease dementia or related tauopathies who might benefit from future therapies emerging from this line of research.
✕Less likely to help
Direct benefits to patients are not guaranteed; findings may primarily advance basic understanding and early-stage targets.
What this research studies
This project uses simple models like C. elegans, test-tube systems, and primary neurons to understand how mutant tubulin changes the way tau interacts with the cell’s skeleton. By comparing tubulin levels, reconstituted systems, and neuron behavior, the research aims to uncover mechanisms that could lead to new treatment strategies for tau-related neurodegeneration. The work is designed to illuminate how cytoskeletal changes influence tau pathology and potentially guide future therapies.
Why it matters
Potential benefit: If successful, the work could reveal new targets in the cytoskeleton to slow or modify tau-related brain damage in Alzheimer’s disease.
How similar studies have gone: Previous models have shown that cytoskeletal components can influence tau pathology, supporting the potential for translation, though human efficacy remains to be demonstrated.
Where this research is happening
-
Seattle Inst for Biomedical/clinical Res
Seattle, United States Active
Researchers
- Principal investigator: Benbow, Sarah Jean Zimmerman — Seattle Inst for Biomedical/clinical Res
- Study coordinator: Benbow, Sarah Jean Zimmerman
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.